FLT3 and acute myeloid leukemia: Across 18 studies, the prevalence of FLT3‐ITD and nucleophosmin (NPM1) co‐mutations was 0.9%–28.0% among AML patients, with the prevalence of NPM1 mutations ranging from 9.0%–60.0% among patients with FLT3‐ITD mutations [11, 13, 14, 17, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38].